Targeting the Calcium Channel for New Migraine Drugs
Dr. Jos� Fern�ndez-Fern�ndez of the Pompeu Fabra University in Barcelona, Spain recently completed his research project on targeting the calcium channel for novel migraine drugs. There is a huge unmet need for effective, safe and reliable migraine treatments that have minimal side effects. In his study, Dr. Fern�ndez-Fern�ndez identified 2 molecules that demonstrated anti-hemiplegic migraine therapeutic potential.
Calcium channel mutations play a critical role in hemiplegic migraine and possibly migraine in general. These mutations can enhance the excitatory function which triggers the headache. In an earlier MRF grant, Dr. Fern�ndez-Fern�ndez looked for agents that could selectively inhibit or desensitize the hyper-excitability caused by the mutations in this channel and identified 6 new molecules. In this MRF grant, he tested these novel inhibitors and found two that modulated the calcium channel activity and reduced the production of undesired side effects.
There's an urgent need for more information about the underlying mechanisms of migraine so that better treatments can be found. Dr. Fern�ndez-Fern�ndez' research will provide a foundation for further analysis of this mechanism of action and pave the way for future development of new anti-migraine drugs.
|